PURPOSE: Diabetes mellitus (DM) is associated with a decreased risk of prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
However, previous studies examining the associations between DM and prostate cancer prognosis have produced mixed results. We aimed to summarize the impact of DM on prostate cancer prognosis.
METHODS: We searched the database of PubMed from inception through March 31, 2014, for articles evaluating the effect of diabetes on outcome in prostate cancer patients, and a meta-analysis was conducted.
RESULTS: A total of 11 cohort studies were included in this meta-analysis, of which 7 studies were carried out to investigate whether DM is associated with the incidence of all-cause mortality among those with prostate cancer, 7 studies to investigate whether DM is associated with prostate cancer-specific mortality, and 2 studies to investigate the relationship of DM and non-prostate cancer mortality. The meta-analysis results suggested that DM could significantly affect the incidence of all-cause mortality among those with prostate cancer (HR = 1.50, 95% CI =1.25-1.79). Besides, DM was also associated with prostate cancer-specific mortality (HR = 1.26, 95% CI = 1.20-1.33) and non-prostate cancer mortality (HR = 1.83, 95% CI = 1.33-2.52) separately. There was no obvious publication bias among the studies included.
CONCLUSION: These results of this meta-analysis reveal an association of DM with adverse prognosis among those with prostate cancer. The biological basis of the contrasting association of DM on prostate cancer incidence and prognosis remains unclear. Doctors could pay more attention to prostate patients with pre-existing DM, and more aggressive treatment regimens should be required. This article is protected by copyright.
Cai H, Xu Z, Xu T, Yu B, Zou Q. Are you the author?
Department of Urologic Surgery, The affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China.
Reference: Diabetes Metab Res Rev. 2014 Jul 28. Epub ahead of print.